Corbus Pharmaceuticals (NASDAQ:CRBP) Director Yong Ben Sells 2,000 Shares of Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Director Yong Ben sold 2,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $7.84, for a total value of $15,680.00. Following the transaction, the director owned 9,383 shares in the company, valued at approximately $73,562.72. This trade represents a 17.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ:CRBP opened at $6.92 on Wednesday. The stock has a market capitalization of $129.20 million, a P/E ratio of -1.12 and a beta of 2.63. The business has a 50-day moving average of $9.70 and a two-hundred day moving average of $9.44. Corbus Pharmaceuticals Holdings, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55). As a group, research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -5.62 EPS for the current fiscal year.

Institutional Trading of Corbus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Orbimed Advisors LLC grew its position in Corbus Pharmaceuticals by 8.8% during the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock worth $16,313,000 after buying an additional 140,000 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Corbus Pharmaceuticals by 76.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock valued at $1,281,000 after acquiring an additional 59,248 shares in the last quarter. Exome Asset Management LLC raised its holdings in Corbus Pharmaceuticals by 67.8% in the 1st quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after acquiring an additional 94,593 shares in the last quarter. Rangeley Capital LLC bought a new stake in shares of Corbus Pharmaceuticals in the 1st quarter worth approximately $421,000. Finally, Engineers Gate Manager LP lifted its position in shares of Corbus Pharmaceuticals by 109.9% in the 2nd quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company’s stock worth $280,000 after acquiring an additional 15,600 shares during the period. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRBP has been the subject of a number of research analyst reports. Mizuho set a $33.00 target price on shares of Corbus Pharmaceuticals in a research report on Thursday, August 13th. Wall Street Zen downgraded Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday. Wedbush cut their price objective on Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, May 27th. Finally, Oppenheimer decreased their target price on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.00.

Trending Headlines about Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Corbus reported positive topline results from the CANYON-1 Phase 1b trial of oral CRB-913 in obesity. The 60 mg dose produced statistically significant, clinically meaningful average weight loss of 5% after 12 weeks, with no plateau observed. The drug was generally well tolerated, with psychiatric adverse events broadly comparable to GLP-1 medicines and an emerging favorable gastrointestinal tolerability profile. Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study
• Positive Sentiment: The data support CRB-913’s potential as an oral, non-incretin obesity treatment, and the company plans a late-breaking presentation at ObesityWeek 2026. The results prompted HC Wainwright to reaffirm its “buy” rating and maintain a $35 price target, implying substantial upside from recent levels. Corbus Pharmaceuticals Obesity Drug Avoids Depressive Effects
• Neutral Sentiment: Trading in CRBP options was unusually active, with call purchases approximately 523% above typical volume on Monday. This may indicate speculative interest following the trial announcement, but it does not establish the direction of the stock.
• Negative Sentiment: Put-option purchases surged approximately 690% above average on Tuesday, signaling increased bearish hedging or speculation and potentially contributing to short-term selling pressure.
• Negative Sentiment: Director Yong Ben sold 2,000 shares for approximately $15,680, reducing his position by 17.57%. While the transaction is relatively small, insider selling can weigh on investor sentiment.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research programs are designed to target biological pathways involved in tumor growth, immune regulation and tissue fibrosis.

Corbus’s oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, a protein expressed on several solid tumors. The company is also developing CRB-601, an investigational monoclonal antibody directed at the alpha v beta 6 integrin, a target associated with tumor biology and fibrotic disease.